Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

BACKGROUND Coronary artery disease occurs in an accelerated fashion in the donor heart after heart transplantation (TxCAD), but the cause is poorly understood. The risk of developing TxCAD is increased by cytomegalovirus (CMV) infection and decreased by use of calcium blockers. Our group observed that prophylactic administration of ganciclovir early after heart transplantation inhibited CMV illness, and we now propose to determine whether this therapy also prevents TxCAD. METHODS AND RESULTS One hundred forty-nine consecutive patients (131 men and 18 women aged 48+/-13 years) were randomized to receive either ganciclovir or placebo during the initial 28 days after heart transplantation. Immunosuppression consisted of muromonab-CD3 (OKT-3) prophylaxis and maintenance with cyclosporine, prednisone, and azathioprine. Mean follow-up time was 4.7+/-1.3 years. In a post hoc analysis of this trial designed to assess efficacy of ganciclovir for prevention of CMV disease, we compared the actuarial incidence of TxCAD, defined by annual angiography as the presence of any stenosis. Because calcium blockers have been shown to prevent TxCAD, we analyzed the results by stratifying patients according to use of calcium blockers. TxCAD could not be evaluated in 28 patients because of early death or limited follow-up. Among the evaluable patients, actuarial incidence of TxCAD at follow-up (mean, 4.7 years) in ganciclovir-treated patients (n=62) compared with placebo (n=59) was 43+/-8% versus 60+/-10% (P<0.1). By Cox multivariate analysis, independent predictors of TxCAD were donor age >40 years (relative risk, 2.7; CI, 1.3 to 5.5; P<0.01) and no ganciclovir (relative risk, 2.1; CI, 1.1 to 5.3; P=0.04). Stratification on the basis of calcium blocker use revealed differences in TxCAD incidence when ganciclovir and placebo were compared: no calcium blockers (n=53), 32+/-11% (n=28) for ganciclovir versus 62+/-16% (n=25) for placebo (P<0.03); calcium blockers (n=68), 50+/-14% (n=33) for ganciclovir versus 45+/-12% (n=35) for placebo (P=NS). CONCLUSIONS TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers. Given the limitations imposed by post hoc analysis, a randomized clinical trial is required to address this issue.

[1]  J. Grundy,et al.  Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. , 1996, Transplantation.

[2]  M. Leon,et al.  Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. , 1996, The New England journal of medicine.

[3]  T. Merigan,et al.  Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. , 1995, Transplantation.

[4]  M. Daemen,et al.  Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. , 1995, Circulation.

[5]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[6]  K. Lemström,et al.  Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. , 1994, Circulation.

[7]  M. Leon,et al.  Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. , 1994, Science.

[8]  M. Nieminen,et al.  Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  S. Hunt,et al.  A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. , 1993, The New England journal of medicine.

[10]  S. Hunt,et al.  Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  P. Reddy,et al.  Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  T. Merigan,et al.  A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. , 1992, The New England journal of medicine.

[13]  J. Thyberg,et al.  Regulation of differentiated properties and proliferation of arterial smooth muscle cells. , 1990, Arteriosclerosis.

[14]  R. Hetzer,et al.  Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. , 1990, The Journal of heart transplantation.

[15]  H. Valantine.  Long-term management and results in heart transplant recipients. , 1990, Cardiology clinics.

[16]  S. Hunt,et al.  Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. , 1989, Circulation.

[17]  T. Rector,et al.  Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. , 1989, The American journal of cardiology.

[18]  V. Starnes,et al.  Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. , 1989, JAMA.

[19]  J F Silverman,et al.  Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. , 1988, Journal of the American College of Cardiology.

[20]  W. Parmley.  Calcium channel blockers and atherogenesis. , 1987, The American journal of medicine.